



# BENJAMIN D EHST, MD, PhD

1750 S Harbor Way, Suite 330  
Portland, Oregon 97201  
p - (503) 245-1525, f - (503) 245-0315  
behst@oregonmedicalresearch.com

---

## PROFESSIONAL EXPERIENCE

---

MEDICAL STAFF	<b>Dermatologist</b> <i>Broadway Medical Clinic, Portland, OR</i>	2021 - PRESENT
	<b>Investigator</b> <i>Oregon Medical Research Center, Portland, OR</i>	2016 - PRESENT
	<b>Dermatologist</b> <i>Baker Allergy, Asthma and Dermatology, Portland, OR</i>	2016 - 2020
	<b>Dermatologist</b> <i>HealthPartners, St. Paul, MN</i> <i>Regions Hospital, St. Paul, MN</i>	2015 - 2017
	<b>Dermatologist</b> <i>Oregon Health &amp; Science University, Portland, OR</i> <i>Veteran's Administration Medical Center, Portland, OR</i>	2007 - 2015
	<b>Dermatologist, Consultants in Dermatology, LLC</b> <i>Mid-Columbia Medical Center, The Dalles, OR</i> <i>Providence Seaside Medical Center, Seaside, OR</i>	2007 - 2012 2007 - 2008
ACADEMIC	<b>Clinical Associate Professor</b>	2017 - PRESENT
	<b>Associate Professor</b>	2015
	<b>Assistant Professor</b> <i>Department of Dermatology,</i> <i>Oregon Health &amp; Science University, Portland, OR</i>	2007 - 2015
	<b>Post-doctoral Research Fellow</b> <i>Department of Molecular Microbiology and Immunology,</i> <i>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD</i> <i>Fidel Zavala, MD, Advisor</i>	2007
	<b>Post-doctoral Research Fellow</b>	2003
	<b>Graduate Research Assistant</b> <i>Department of Microbiology and Center for Immunology,</i> <i>University of Minnesota, Minneapolis, MN</i> <i>Marc K. Jenkins, PhD, Advisor</i>	1998 - 2001

	<b>Research Assistant</b> <i>Ben May Institute for Cancer Research and Committee on Immunology, University of Chicago, Chicago, IL Jeffrey A. Bluestone, PhD, Advisor</i>	1995 - 1996
ADMINISTRATIVE	<b>Owner and President</b> <i>Oregon Medical Research Center, Portland, OR</i>	2023 - PRESENT
	<b>Director</b> , Medical Dermatology <i>Department of Dermatology, Oregon Health &amp; Science University, Portland, OR</i>	2010 - 2014
	<b>Director</b> , Consultants in Dermatology, LLC <i>Providence Seaside Medical Center, Seaside, OR and Mid-Columbia Medical Center, The Dalles, OR</i>	2010 - 2013
	<b>Director</b> , Dermatology Undergraduate Medical Education <i>Department of Dermatology, Oregon Health &amp; Science University, Portland, OR</i>	2007 - 2010
CONSULTANCY	<i>AnaptysBio, Inc., San Diego, CA</i> Chief investigator for atopic dermatitis clinical trial ANBo32-201	2023 – PRESENT
	<i>Arcutis Biotherapeutics, Inc., Westlake Village, CA</i> Advisory board member for dermatologic disease platform including roflumilast cream	2021 – PRESENT
	<i>Incyte Corporation, Wilmington, DE</i> National speaker board member for dermatologic disease platform including ruxolitinib cream for vitiligo and atopic dermatitis	2021 – PRESENT
	<i>UCB, Inc., Smyrna, GA</i> Advisory board and national speaker board member for psoriatic disease platform including bimekizumab biologic therapy	2021 – PRESENT
	<i>Dermavant Sciences, Inc., Morrisville, NC</i> Consultant, advisory board and national speaker board member for tapinarof cream for psoriasis and atopic dermatitis	2020 – PRESENT
	<i>LEO Pharma, Inc., Madison, NJ</i> Consultant, advisory board and national speaker board member for Atopic dermatitis disease platform including tralokinumab biologic therapy; international coordinating investigator for chronic atopic hand eczema clinical trial LPo162-2328	2020 – PRESENT
	<i>AbbVie Inc., North Chicago, IL</i>	2019 – PRESENT

Advisory board and national speaker board member for psoriatic and atopic disease platforms including adalimumab, risankizumab and upadacitinib therapies	2015 – 2016
<i>Evelo Biosciences, Inc.</i> , Cambridge, MA Consultant and advisory board member for dermatologic disease platform; chief investigator for psoriasis and atopic dermatitis clinical trials EDP1815-201, EDP1815-207	2019 – PRESENT
<i>Generate Bio, LLC</i> , Roslyn Harbor, NY Consultant for dermatologic disease platform	2019 – PRESENT
<i>Janssen Biotech, Inc.</i> , Horsham, PA Advisory board member for psoriatic disease platform including ustekinumab and guselkumab biologic therapies	2018 – PRESENT 2014 – 2016
<i>Novartis Pharmaceuticals Corp.</i> , East Hanover, NJ Advisory board and national speaker board member for psoriatic and hidradenitis disease platforms including secukinumab biologic therapy	2017 – PRESENT
<i>Regeneron Pharmaceuticals, Inc.</i> , Tarrytown, NY <i>Sanofi-Aventis US, LLC – Dermatology</i> , Bridgewater, NJ Advisory board and national speaker board member for dermatologic disease platform including dupilumab biologic therapy	2017 – PRESENT
<i>Eli Lilly and Co.</i> , Indianapolis, IN Advisory board and national speaker board member for psoriatic and atopic disease platform including ixekizumab and baricitinib therapies	2017 – PRESENT 2014 – 2016
<i>Priovant Therapeutics, Inc.</i> , New York, NY Consultant for dermatologic disease platform	2022 – 2023
<i>TRPblue, Inc.</i> , Durham, NC Consultant for atopic dermatitis disease platform	2019 – 2022
<i>Bausch Health US, LLC – Ortho Dermatologics</i> , Bridgeport, NJ Advisory board and national speaker board member for psoriatic disease platform including brodalumab biologic therapy	2019 – 2022
<i>Oregon Aesthetic Technologies</i> , Portland, OR Consultant on clinical trial design of BEAM device for acne vulgaris	2010
<i>Meagan Medical, Inc</i> , Vancouver, WA Consultant on cutaneous field-stimulator device for chronic pain	2009 - 2010

## SPECIALTY CERTIFICATION

*Diplomate, American Board of Dermatology, No. 2007-016361*

2007  
*Re-certified, 2017*

## LICENSE

*Oregon, active status (expires 12/31/2023), No. MD27612*

*Granted, 2007*

## EDUCATION

---

POST-GRADUATE	<b>JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE,</b> BALTIMORE, MD <i>Resident, Department of Dermatology</i>	2004 - 2007
	<b>UNIVERSITY OF SÃO PAULO, SÃO PAULO, BRAZIL</b> <i>Visiting Resident, Department of Dermatology</i>	2006
	<b>HENNEPIN COUNTY MEDICAL CENTER, MINNEAPOLIS, MN</b> <i>Chief Resident, Transitional Internship</i>	2003 - 2004
GRADUATE	<b>UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN</b> Combined MD/PhD Program MD (2003) PhD (2002), <i>Microbiology, Immunology and Cancer Biology</i>	1996 - 2003
UNDERGRADUATE	<b>UNIVERSITY OF CHICAGO, CHICAGO, IL</b> AB with Honors, <i>Biological Sciences</i>	1992 - 1996

## SCHOLARSHIP

---

### RESEARCH INTERESTS

Dermatologic manifestations of HIV and other infectious diseases; Immunobiology of psoriasis, atopic dermatitis and other inflammatory skin diseases; Infectious complications of immunomodulating biologic drug use

### GRANTS

<i>Co-Principal Investigator, National Institute of Arthritis and Musculoskeletal and Skin Diseases, R03</i> <i>“PIASy as a negative regulator of Th17 pathway in psoriasis”; Co-PI: Yuangang Liu, PhD</i>	2014 - 2015
<i>Sub-I, National Institute of Allergy and Infectious Diseases</i>	2012 - 2015

Investigator-Initiated Study, “A Randomized Open Label Mechanistic Study with Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines”; PI: Jon Hanifin, MD

*Sub-I*, National Institute of Allergy and Infectious Diseases 2007 - 2015  
Investigator-Initiated Study, “A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects”;  
PI: Jon Hanifin, MD

*Sub-I*, National Institute of Arthritis and Musculoskeletal and Skin Diseases 2006 - 2011  
Investigator-Initiated Study, “Role of IL-23 and other cytokines in psoriasis and atopic dermatitis pathogenesis”; PI: Andrew Blauvelt, MD

*Sub-I*, National Institute of Allergy and Infectious Diseases, 2008 - 2010  
“ADV N Analysis of the Response of subjects with atopic Dermatitis to Oral Vitamin D<sub>3</sub> by Measurement of Antimicrobial Peptide Expression in Skin and Saliva (Protocol ADV N CATH 03)”; PI: Jon Hanifin, MD

*Principal Investigator*, Dermatology Foundation, Patient-Directed Investigation Grant, 2008 - 2009  
“Effects of TNF antagonist therapy on immunity to infectious pathogens in individuals with psoriasis”

#### **SPONSORED STUDIES**

*Principal Investigator*, AbbVie Inc. 2023  
“A phase 4 multicenter, randomized, double-blind study of risankizumab for the treatment of adult subjects with moderate to severe genital psoriasis or moderate to severe scalp psoriasis”

*Principal Investigator*, Acelyrin Inc. 2023  
“A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis suppurativa”

*Principal Investigator*, Alumis Inc. 2023  
“An open-label extension study to evaluate the long-term safety and efficacy of ESK-001 in patients with plaque psoriasis”

*Principal Investigator*, Amgen, Inc. 2023  
“A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ≥ 12 to < 18 years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)”

*Principal Investigator*, Amgen, Inc. 2023  
“A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)”

*Principal Investigator*, Amgen, Inc. 2023

<p>“A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)”</p> <p><i>Principal Investigator, AnaptysBio, Inc.</i></p> <p>“A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ANBo32 in the treatment of subjects with moderate to severe atopic dermatitis”</p>	2023
<p><i>Principal Investigator, Bristol-Myers Squibb Company</i></p> <p>“A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate clinical efficacy and safety of deucravacitinib (BMS-986165) in participants with alopecia areata”</p>	2023
<p><i>Principal Investigator, DermBiont, Inc.</i></p> <p>“Randomized double-blind vehicle-controlled study of the safety and efficacy of SM-020 gel 1.0% in subjects with seborrheic keratosis”</p>	2023
<p><i>Principal Investigator, Incyte Corporation</i></p> <p>“A phase 2, double-blind, randomized, 16-week, vehicle-controlled, efficacy and safety study of ruxolitinib cream followed by an open-label extension period in adults with chronic hand eczema”</p>	2023
<p><i>Principal Investigator, Incyte Corporation</i></p> <p>“A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa”</p>	2023
<p><i>Principal Investigator, Incyte Corporation</i></p> <p>“A Phase 2, Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus”</p>	2023
<p><i>Principal Investigator, AbbVie, Inc.</i></p> <p>“A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to Severe Atopic Dermatitis (Level-Up)”</p>	2022
<p><i>Principal Investigator, Acelyrin Inc.</i></p> <p>“A phase 2b pivotal study to evaluate the efficacy and safety of izokibep in subjects with moderate to severe hidradenitis suppurativa”</p>	2022
<p><i>Principal Investigator, Allakos Inc.</i></p> <p>“A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects with H-1 Antihistamine Refractory Chronic Spontaneous Urticaria”</p>	2022
<p><i>Principal Investigator, Dermavant Sciences Ltd.</i></p> <p>“An open-label, long-term extension study to evaluate the safety and efficacy of tapinarof cream 1% in subjects with atopic dermatitis”</p>	2022

<p><i>Principal Investigator</i>, Evelo Biosciences, Inc.  “A phase 2, multicenter, double-blind, placebo-controlled, multiple-cohort study investigating the effect of EDP-1815 in participants for the treatment of mild, moderate and severe atopic dermatitis”</p>	2022
<p><i>Principal Investigator</i>, Evelo Biosciences, Inc.  “A long-term extension trial in participants with atopic dermatitis who participated in previous phase 2 and 3 EDP-1815 trials”</p>	2022
<p><i>Sub-I</i>, Oregon Medical Research Center and AbbVie, Inc.  Investigator-Initiated Study, “Decreasing resident memory T cells while increasing clinical durability: higher induction doses of risankizumab for moderate-to-severe plaque psoriasis (KNOCKOUT)”; PI: Andrew Blauvelt, MD</p>	2022
<p><i>Sub-I</i>, Kymab Ltd.  “A phase IIb, randomized, double-blind, placebo-controlled, parallel group, multicentre dose ranging study of a subcutaneous anti-OX40L monoclonal antibody (KY1005) in moderate to severe atopic dermatitis”; PI: Andrew Blauvelt</p>	2022
<p><i>Sub-I</i>, Evommune, Inc.  “A randomized, vehicle-controlled, safety and efficacy study of EVO101 in adult subjects with atopic dermatitis”; PI: Andrew Blauvelt</p>	2022
<p><i>Sub-I</i>, Alumis Inc.  “A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis”; PI: Andrew Blauvelt</p>	2022
<p><i>Sub-I</i>, Bristol-Myers Squibb Company  “A phase 3B/4, multicenter, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of deucravacitinib in participants with moderate-to-severe scalp psoriasis (PSORIATYK SCALP)”; PI: Andrew Blauvelt</p>	2022
<p><i>Sub-I</i>, Ventyx Biosciences, Inc.  “A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of VTX958 in participants with moderate to severe psoriasis”; PI: Andrew Blauvelt</p>	2022
<p><i>Sub-I</i>, Concert Pharmaceuticals, Inc.  “A multicenter, open-label, extension study to assess the long-term safety and efficacy of CTP-543 in adult patients with moderate to severe alopecia areata”; PI: Andrew Blauvelt</p>	2022
<p><i>Sub-I</i>, Almirall, S.A.  “A phase 3, multicenter, open-label, single-arm study to evaluate the safety and tolerability of tirbanibulin ointment 1% applied to a field of approximately 100 cm<sup>2</sup> on the face or balding scalp in adult patients with actinic keratosis”; PI: Andrew Blauvelt</p>	2022
<p><i>Principal Investigator</i>, Dermavant Sciences Ltd.</p>	2021

“A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults”

*Sub-I*, AbbVie Inc.

2021

“A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate the safety and efficacy of upadacitinib in subjects with non-segmental vitiligo”; PI: Andrew Blauvelt, MD

*Sub-I*, Arcutis Biotherapeutics, Inc.

2021

“A Phase 3, 8-week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis (STRATUM)”; PI: Andrew Blauvelt, MD

*Sub-I*, Arcutis Biotherapeutics, Inc.

2021

“A Phase 3, 8-week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Scalp and Body Psoriasis (ARRECTOR)”; PI: Andrew Blauvelt, MD

*Sub-I*, Celgene International II Sàrl

2021

“A phase 2, multicenter, global, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of cendakimab (CC-93538) in adult subjects with moderate to severe atopic dermatitis”; PI: Andrew Blauvelt

*Sub-I*, Concert Pharmaceuticals, Inc.

2021

“A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of CTP-543 in adult patients with moderate to severe alopecia areata”; PI: Andrew Blauvelt

*Sub-I*, Incyte Corporation

2021

“A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo”; PI: Andrew Blauvelt, MD

*Sub-I*, Eli Lilly and Company

2021

“A phase 3, 16-week, randomized, double-blind, placebo-controlled, parallel-group study to assess the impact of lebrikizumab on vaccine responses in adults patients with moderate-to-severe atopic dermatitis”; PI: Andrew Blauvelt

*Sub-I*, Arcutis Biotherapeutics, Inc.

2021

“A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis”; PI: Andrew Blauvelt, MD

*Sub-I*, Arcutis Biotherapeutics, Inc.

2021

“A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis”; PI: Andrew Blauvelt, MD



<p><i>Sub-I</i>, Amgen, Inc.  “A Multicenter, Randomized, Double-blinded Study Evaluating the Pharmacokinetics, Efficacy and Safety of Multiple Switches Between Ustekinumab and ABP 654 Compared With Continued Use of Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis”; PI: Andrew Blauvelt, MD</p>	2021
<p><i>Sub-I</i>, Amgen, Inc.  “A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared with Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis”; PI: Andrew Blauvelt, MD</p>	2021
<p><i>Principal Investigator</i>, Evelo Biosciences, Inc.  “A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort, Dose-Ranging Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis”</p>	2020
<p><i>Principal Investigator</i>, Novartis Pharmaceuticals Corp.  “A proof of concept study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven lichen planus not adequately controlled with topical therapies – PRELUDE”</p>	2020
<p><i>Principal Investigator</i>, Dermavant Sciences Ltd.  “A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults”</p>	2020
<p><i>Sub-I</i>, AbbVie Inc.  ‘A Phase 3b, open-label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who completed treatment in Study M16-046’; PI: Andrew Blauvelt, MD</p>	2020
<p><i>Sub-I</i>, Bristol-Myers Squibb Company  “An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis”; PI: Andrew Blauvelt, MD</p>	2020
<p><i>Sub-I</i>, Eli Lilly and Company  “A long-term study to assess the safety and efficacy of lebrikizumab in patients with moderate to severe atopic dermatitis”; PI: Andrew Blauvelt</p>	2020
<p><i>Sub-I</i>, Eli Lilly and Company  “A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrikizumab when used in combination with topical corticosteroid treatment in patients with moderate to severe atopic dermatitis”; PI: Andrew Blauvelt</p>	2020
<p><i>Sub-I</i>, Pfizer, Inc.  “A phase 3 open-label, multi-center, long-term study investigating the safety and efficacy of PF-06651600 in adult and adolescent participants with alopecia areata”;</p>	2020

PI: Andrew Blauvelt

<i>Sub-I</i> , Pfizer, Inc. “A study to assess the safety and efficacy of abrocitinib compared with dupilumab in adult participants with moderate to severe atopic dermatitis”; PI: Andrew Blauvelt	2020
<i>Principal Investigator</i> , AbbVie Inc. “A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa”	2019
<i>Principal Investigator</i> , Dermavant Sciences Ltd. “A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults”	2019
<i>Principal Investigator</i> , LEO Pharma A/S “A phase 2b, double-blind, randomised, 5-arm, vehicle-controlled, dose-ranging trial to evaluate the efficacy and safety of twice daily topical application of delgocitinib cream 1, 3, 8, and 20 mg/g for 16 weeks in adult subjects with mild to severe chronic hand eczema”	2019
<i>Principal Investigator</i> , Novan, Inc. “A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum”	2019
<i>Sub-I</i> , AbbVie Inc. “A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis”; PI: Andrew Blauvelt, MD	2019
<i>Sub-I</i> , AbbVie Inc. “A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis”; PI: Andrew Blauvelt, MD	2019
<i>Sub-I</i> , Eli Lilly and Company “A 24-Week Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis”; PI: Andrew Blauvelt, MD	2019
<i>Sub-I</i> , Eli Lilly and Company “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata”; PI: Andrew Blauvelt, MD	2019
<i>Sub-I</i> , Dermira, Inc.	2019

<p>“A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrikizumab in patients with moderate to severe atopic dermatitis”; PI: Andrew Blauvelt</p>	
<p><i>Sub-I</i>, Sun Pharma “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp”; PI: Andrew Blauvelt, MD</p>	2019
<p><i>Sub-I</i>, Bristol-Myers Squibb Company “A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis”; PI: Andrew Blauvelt, MD</p>	2019
<p><i>Sub-I</i>, Incyte Corporation “A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis”; PI: Andrew Blauvelt, MD</p>	2019
<p><i>Sub-I</i>, Incyte Corporation “A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo”; PI: Andrew Blauvelt, MD</p>	2019
<p><i>Sub-I</i>, Incyte Corporation “A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo”; PI: Andrew Blauvelt, MD</p>	2019
<p><i>Sub-I</i>, Aclaris Therapeutics, Inc. “Open-Label Study of ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)”; PI: Andrew Blauvelt, MD</p>	2019
<p><i>Sub-I</i>, Eli Lilly and Company “A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis OASIS-3”; PI: Andrew Blauvelt, MD</p>	2019
<p><i>Principal Investigator</i>, Janssen Pharmaceuticals, Inc. “A phase 2, multicenter, randomized, placebo-controlled, double-blind, proof-of-concept study to evaluate guselkumab for the treatment of subjects with moderate to severe hidradenitis suppurativa”</p>	2018
<p><i>Principal Investigator</i>, UCB Biopharma “A phase 3, multicenter, randomized, double-blind, parallel-group, placebo- and active-controlled study followed by a placebo-controlled maintenance period and</p>	2018

open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis (CIMPACT”);  
Sub-I: 2016-2018

*Principal Investigator*, Vidac Pharma 2018  
“A Phase 2B Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects with Actinic Keratosis”

*Sub-I*, AbbVie Inc. 2018  
“A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy”; PI: Andrew Blauvelt, MD

*Sub-I*, Aclaris Therapeutics, Inc. 2018  
“A phase 2A safety study of ATI-502 topical solution in subjects with moderate to severe atopic dermatitis.”

*Sub-I*, Aclaris Therapeutics, Inc. 2018  
“A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-501 Oral Suspension Compared to Placebo in Adult Subjects with Alopecia Areata, Alopecia Universalis or Alopecia Totalis; PI: Andrew Blauvelt, MD

*Sub-I*, Dermira, Inc. 2018  
“A randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate the efficacy and safety of lebrikizumab in the patients with moderate to severe atopic dermatitis”; PI: Andrew Blauvelt

*Sub-I*, Dermavant Sciences Ltd. 2018  
“Phase 2 study to evaluate the efficacy, safety, and tolerability of RVT-501 topical ointment in pediatric patients with mild to moderate atopic dermatitis”; PI: Andrew Blauvelt, MD

*Sub-I*, Eli Lilly and Company 2018  
“A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis (OASIS-1)”; PI: Andrew Blauvelt, MD

*Sub-I*, LEO Pharma A/S 2018  
“An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab clinical trials”; PI: Andrew Blauvelt

*Sub-I*, LEO Pharma A/S 2018

“A randomised, double-blind, placebo-controlled, parallel-group, multi-centre trial to evaluate the efficacy, safety, and tolerability of tralokinumab monotherapy in adolescent subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy”; PI: Andrew Blauvelt

*Sub-I, UCB Biopharma*

2018

“A phase 3, multicenter, double-blind, placebo-controlled study with an initial treatment period followed by a randomized withdrawal period to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD

*Sub-I, UCB Biopharma*

2018

“A phase 3, multicenter, randomized, double-blind study with an active-controlled initial treatment period followed by a dose-blind maintenance treatment period to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD

*Sub-I, UCB Biopharma*

2018

“A multicenter, randomized, double-blind, secukinumab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD

*Sub-I, UCB Biopharma*

2018

“A multicenter, open-label study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD

*Sub-I, Pfizer, Inc.*

2018

“A phase 3 randomized, double-blind, multi-center, long-term extension study investigating the efficacy and safety of PF-04965842, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis”; PI: Andrew Blauvelt

*Sub-I, Allergan plc*

2018

“A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis”; PI: Andrew Blauvelt, MD

*Sub-I, Realm Therapeutics, Inc.*

2018

“A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group, Phase 2a Study to Assess the Safety and Efficacy of PRO22 Gel in Adults with Mild-to-Moderate Atopic Dermatitis”; PI: Andrew Blauvelt, MD

*Sub-I, Athenex, Inc.*

2017

“A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or Scalp”; PI: Andrew Blauvelt, MD

<p><i>Sub-I</i>, LEO Pharma A/S          “Tralokinumab monotherapy for moderate-to-severe atopic dermatitis (ECZTRA 1”);          PI: Andrew Blauvelt, MD</p>	2017
<p><i>Sub-I</i>, Sienna Biopharmaceuticals, Inc.          “A Randomized, Double-Blind, Placebo-Controlled Phase 2b, Multicenter Study To Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib Ointment) in Subjects with Pruritus Associated with Psoriasis Vulgaris”; PI: Andrew Blauvelt, MD</p>	2017
<p><i>Sub-I</i>, Revance Therapeutics, Inc.          “An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines; PI: Robert Matheson, MD</p>	2017
<p><i>Sub-I</i>, Regeneron Pharmaceuticals, Inc.          “A Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Dupilumab Monotherapy In Patients &gt;12 To &lt;18 Years Of Age, With Moderate-To-Severe Atopic Dermatitis”; PI: Andrew Blauvelt, MD</p>	2017
<p><i>Sub-I</i>, Regeneron Pharmaceuticals, Inc.          “An open-label, randomized, actual use study of dupilumab auto-injector device in patients with atopic dermatitis”; PI: Andrew Blauvelt, MD</p>	2017
<p><i>Sub-I</i>, Janssen Pharmaceuticals, Inc.          “A phase 3, multicenter, randomized, double-blind study evaluating the comparative efficacy of CNTO 1959 (guselkumab) and secukinumab for the treatment of moderate to severe plaque-type psoriasis (ECLIPSE)”; PI: Andrew Blauvelt, MD</p>	2017
<p><i>Sub-I</i>, Dermavant Sciences Ltd.          “Phase 2 study of RVT-501 in adult and adolescent subjects with atopic dermatitis”;          PI: Andrew Blauvelt, MD</p>	2017
<p><i>Sub-I</i>, Allergan plc          “Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males with a Comparator Arm”;          PI: Andrew Blauvelt, MD</p>	2017
<p><i>Sub-I</i>, GlaxoSmithKline plc          “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects with Moderate to Severe Atopic Dermatitis”; PI: Andrew Blauvelt, MD</p>	2017
<p><i>Sub-I</i>, Novartis Pharmaceuticals Corp.          “A randomized, double-blind, placebo-controlled, parallel group, multicenter study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab, compared to placebo, and up to 52 weeks</p>	2017

of treatment with secukinumab in adult patients with moderate to severe plaque psoriasis (ADIPSO)”; PI: Andrew Blauvelt, MD	
<i>Sub-I</i> , AbbVie Inc. “A multicenter, open label study to assess the safety of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS)”; PI: Andrew Blauvelt, MD	2017
<i>Sub-I</i> , Regeneron Pharmaceuticals, Inc. “An open-label study of dupilumab in patients with atopic dermatitis who participated in previous duplimumab trials”; PI: Andrew Blauvelt, MD	2016
<i>Sub-I</i> , Eli Lilly and Company “A multicenter, randomized, double-blind study comparing the efficacy and safety of ixekizumab versus placebo in patients with moderate-to-severe genital psoriasis”; PI: Andrew Blauvelt, MD	2016
<i>Sub-I</i> , Eli Lilly and Company “A multicenter study with a randomized, double-blind placebo-controlled induction dosing period followed by a randomized maintenance dosing period and a long-term extension period to evaluate the efficacy and safety of LY2439821 in patients with moderate-to-severe plaque psoriasis (UNCOVER-1)”; PI: Andrew Blauvelt, MD	2016
<i>Sub-I</i> , Eli Lilly and Company “Phase III, 12-week multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of LY2438921 to etanercept and placebo in patients with moderate to severe plaque psoriasis with a long-term extension period (UNCOVER-3)”; PI: Andrew Blauvelt, MD	2016
<i>Sub-I</i> , Nielsen Biosciences Inc. “A phase IIa, randomized, double-blind, placebo-controlled study of the safety and efficacy of varying regimens of CANDIN for treatment of common warts (verruca vulgaris)”; PI: Andrew Blauvelt, MD	2016
<i>Sub-I</i> , Boehringer Ingelheim Pharmaceuticals, Inc. “BI 655066 versus placebo in a multicenter randomized double-blind study in patients with moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment (IMMhance)”; PI: Andrew Blauvelt, MD	2016
<i>Sub-I</i> , Boehringer Ingelheim Pharmaceuticals, Inc. “BI 655066 (risankizumab) versus ustekinumab and placebo comparators in a randomized double blind trial for maintenance use in moderate to severe chronic plaque type psoriasis (UltIMMa-1)”; PI: Andrew Blauvelt, MD	2016
<i>Sub-I</i> , Boehringer Ingelheim Pharmaceuticals, Inc. “An open label extension trial assessing the safety and efficacy of	2016

BI 655066/ABBV-o66/risankizumab administered subcutaneously in patients with moderate to severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD

*Sub-I*, UCB Biopharma

2016

“A phase 3, multicenter, randomized, double-blind, parallel-group, study followed by a dose-blind period and open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis (CIMPASI-2)”; PI: Andrew Blauvelt, MD

*Sub-I*, UCB Biopharma

2016

“A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD

*Sub-I*, UCB Biopharma

2016

“A multicenter, 48-week, double-blind, placebo-controlled, parallel-group extension study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD

*Sub-I*, Novartis Pharmaceuticals Corp.

2016

“A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous secukinumab injections with 2 ml pre-filled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis (ALLURE)”; PI: Andrew Blauvelt, MD

*Sub-I*, Novartis Pharmaceuticals Corp.

2016

“A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis (CLARITY)”; PI: Andrew Blauvelt, MD

*Sub-I*, Novartis Pharmaceuticals Corp.

2016

“A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult subjects with moderate to severe chronic plaque-type psoriasis”; PI: Andrew Blauvelt, MD

*Sub-I*, Merck & Co., Inc.

2016

“A 52-week, phase 3, randomized, active comparator and placebo-controlled, parallel design study to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (SCH 900222/MK-3222), followed by an optional long-term safety extension study, in subjects with moderate-to-severe chronic plaque psoriasis”; PI: Andrew Blauvelt, MD



<p><i>Sub-I</i>, Janssen Pharmaceuticals, Inc.  “Phase 3, multicenter, randomized, double-blind placebo and active comparator-controlled study evaluating the efficacy and safety of CNTO 1959 (guselkumab) in subjects with moderate to severe plaque-type psoriasis (VOYAGE-1);  PI: Andrew Blauvelt, MD</p>	2016
<p><i>Principal Investigator</i>, Amgen, Inc.  “A prospective, observational study to estimate the proportion of subjects with plaque psoriasis who achieve complete clearance on biologics”</p>	2014
<p><i>Principal Investigator</i>, National Heart, Lung and Blood Institute, The University of Pennsylvania, and AbbVie Inc.  “A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease, The Vascular Inflammation in Psoriasis Trial and Extension”</p>	2014
<p><i>Principal Investigator</i>, Stiefel Laboratories, Inc.  “A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety, Efficacy, Systemic Exposure, and Pharmacodynamics of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis”; Sub-I: 2013-2014</p>	2014
<p><i>Sub-I</i>, Novartis Pharmaceuticals Corp.  “Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 4 - LGX818 for Patients with BRAFV600E Mutated Tumors”;  PI: Matthew Taylor, MD</p>	2014
<p><i>Sub-I</i>, Anacor Pharmaceuticals, Inc.  “A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis”;  PI: Eric Simpson, MD</p>	2014
<p><i>Sub-I</i>, Celgene Corporation  “A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Atopic Dermatitis”; PI: Eric Simpson, MD</p>	2014
<p><i>Sub-I</i>, Merck &amp; Co., Inc.  “A randomized, placebo-controlled multiple-rising dose study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of intravenous MK-8226 in adults with atopic dermatitis”; PI: Jon Hanifin, MD</p>	2013
<p><i>Sub-I</i>, Novartis Pharmaceuticals Corp.  “A Phase Ib/II, Multicenter Study of LEE011 in Combination with LGX818 in Adult Patients with BRAF Mutant Melanoma”; PI: Matthew Taylor, MD</p>	2013
<p><i>Sub-I</i>, Regeneron Pharmaceuticals, Inc.  “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging</p>	2013

Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of REGN668 Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis”; PI: Eric Simpson, MD

*Sub-I*, LEO Pharma, Inc. 2013

“Safety and efficacy of escalating doses of ingenol mebutate once daily for two or three consecutive days when used on full face, full balding scalp or approximately 250 cm<sup>2</sup> on the chest in subjects with actinic keratosis. Part 2: A Phase 2, multicentre, randomised, double-blind, parallel group, vehicle-controlled, 8-week trial”; PI: Neil Swanson, MD

*Sub-I*, Hoffman-La Roche, Ltd. 2013

“A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery”; PI: Neil Swanson, MD

*Sub-I*, Regeneron Pharmaceuticals, Inc. 2013

“An open-label study of dupilumab in patients with atopic dermatitis who participated in previous dupilumab clinical trials”; PI: Eric Simpson, MD

*Co-Principal Investigator*, Innovision Therapeutics 2012

“A safety and proof of concept study of topical piperine in subjects with vitiligo”; Co-PI: Amala Soumyanath, PhD

*Principal Investigator*, Merck & Co., Inc. 2012

“A 64-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis”

*Principal Investigator*, Amgen, Inc. 2012

“A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2”

*Sub-I*, LEO Pharma, Inc. 2012

“A Sequential Treatment Regimen of Cryotherapy and Picato<sup>®</sup> (Ingenol Mebutate) gel, 0.015% Field Therapy Compared to Cryotherapy Alone for the Treatment of Actinic Keratosis on the Face and Scalp”; PI: Neil Swanson, MD

*Principal Investigator*, Pfizer, Inc. 2011

“A Phase 3, Multi-Site, Open-Label Study of the Long Term Safety and Tolerability of 2 Oral Doses of CP-690,550 in Subjects With Moderate to Severe Chronic Plaque Psoriasis”

*Principal Investigator*, Abbott Laboratories 2011

“A 10-Year, Post-marketing, Observational, Registry of Humira (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps)”; Sub-I: 2009 - 2011

<p><i>Sub-I, Amgen, Inc.</i></p> <p>“A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects with Moderate to Severe Psoriasis”; PI: Eric Simpson, MD</p>	2011
<p><i>Sub-I, Celgene Corporation</i></p> <p>“A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis”; PI: Eric Simpson, MD</p>	2011
<p><i>Principal Investigator, Pfizer, Inc.</i></p> <p>“A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of 2 Oral Doses of CP-690,550 in Subjects With Moderate to Severe Chronic Plaque Psoriasis”</p>	2011
<p><i>Principal Investigator, Abbott Laboratories</i></p> <p>“M10-016: A Phase 3, Multicenter, Open-label Continuation Study of Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study with ABT-874”; Sub-I: 2008 – 2011</p>	2011
<p><i>Principal Investigator, Centocor Research and Development, Inc.</i></p> <p>“A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis”; Sub-I: 2007 - 2011</p>	2011
<p><i>Sub-I, Regeneron Pharmaceuticals, Inc.</i></p> <p>“A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety and Pharmacokinetics of Subcutaneous REGN668 in Patients with Moderate-to-Severe Extrinsic Atopic Dermatitis”; PI: Eric Simpson, MD</p>	2010
<p><i>Principal Investigator, MacroGenics, Inc.</i></p> <p>“A phase 2a, open label, multiple-dose study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of teplizumab in adults with moderate or more severe psoriasis”</p>	2009
<p><i>Principal Investigator, Medicis Pharmaceuticals</i></p> <p>Investigator-Initiated Study, “Tolerability comparison of clindamycin/tretinoin gel and adapelene/benzoyl peroxide gel for topical treatment of acne vulgaris”</p>	2009
<p><i>Sub-I, Amgen, Inc.</i></p> <p>“A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects with Moderate to Severe Atopic Dermatitis”; PI: Eric Simpson, MD</p>	2009

<p><i>Sub-I</i>, Inhibitex, Inc.  “FV-100 vs. Valacyclovir in Patients with Herpes Zoster”; PI: Jon Hanifin, MD</p>	<p>2009</p>
<p><i>Sub-I</i>, Celgene Corporation  “Celgene Apremilast for Atopic Dermatitis - A Pilot Study in Adults”;  PI: Eric Simpson, MD</p>	<p>2009</p>
<p><i>Sub-I</i>, Taisho Pharmaceuticals R&amp;D, Inc.  “A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy, Safety and Tolerability of TS-022 in Adults with a Diagnosis of Atopic Dermatitis (AD) with Moderate to Very Severe Pruritus”; PI: Jon Hanifin, MD</p>	<p>2009</p>
<p><i>Sub-I</i>, Centocor Ortho Biotech, Inc.  “A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subject with Active Psoriatic Arthritis and Previously Treated with Biologic Anti-TNF<math>\alpha</math> Agent(s)”; PI: Atulya Deodhar, MD</p>	<p>2009</p>
<p><i>Sub-I</i>, Novo Nordisk, Inc.  “A randomised, double-blind, placebo-controlled, single and multiple dose, dose-escalation trial of Anti-IL-20 (109-0012) 100 mg/vial in psoriatic subjects, followed by an expansion phase”; PI: Andrew Blauvelt, MD</p>	<p>2008</p>
<p><i>Sub-I</i>, Basilea Pharmaceutica, Ltd.  “Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy”; PI: Jon Hanifin, MD</p>	<p>2008</p>
<p><i>Sub-I</i>, Eli Lilly and Company  “Protocol IIF-MC-RHAG(d) LY2439821 (Anti-IL-17 Humanized Antibody) Multiple-Dose Safety and Tolerability Study in Subjects with Psoriasis Vulgaris”;  PI: Andrew Blauvelt, MD</p>	<p>2008</p>
<p><i>Sub-I</i>, Pfizer, Inc  “Phase 2A Randomized, Double-Blind, Vehicle-Controlled, Intra-Individual Comparison Trial Assessing Safety, Toleration, Pharmacokinetics, and Pilot Efficacy of 4 Weeks Treatment With Topical CP-690,550 in Chronic Plaque Psoriasis”;  PI: Andrew Blauvelt, MD</p>	<p>2008</p>
<p><i>Sub-I</i>, Gilead Science, Inc.  “A Phase 1, Randomized, Double-blind, Placebo-controlled Assessment of the Safety, Tolerability, and Activity of GS-9191 Ointment for the Treatment of External Genital and Perianal Warts Caused by Human Papilloma Virus Infection”; PI: Eric Simpson, MD</p>	<p>2007</p>

**UNFUNDED STUDIES**

<p><i>Sub-I, Investigator-Initiated Study</i>  “Secukinumab use in psoriasis patients with hepatitis C and hepatitis B”;  PI: Kevin Winthrop, MD</p>	2017
<p><i>Principal Investigator, Investigator-Initiated Study</i>  “Pre-hydration therapy for severe psoriasis”</p>	2014
<p><i>Principal Investigator, Investigator-Initiated Study</i>  “Ustekinumab use in psoriasis patients with hepatitis C and hepatitis B”</p>	2014
<p><i>Principal Investigator, Investigator-Initiated Study</i>  “Repository Database of Patients Prescribed Ustekinumab Therapy at Oregon Health &amp; Science University”</p>	2012
<p><i>Principal Investigator, Investigator-Initiated Study</i>  “Clinical Database for Patients with Psoriasis”; Sub-I: 2008 – 2011</p>	2011
<p><i>Sub-I, Investigator-Initiated Study</i>  “Sensitivity/specificity study of non-invasive imaging for melanoma diagnosis”;  PI: Eric Simpson, MD</p>	2011
<p><i>Principal Investigator, Investigator-Initiated Study</i>  ”Monitoring of patients with granuloma annulare taking combination antibiotic therapy after biopsy for mycobacterial culture”</p>	2010
<p><i>Sub-I, Investigator-Initiated Study</i>  “Presence of Gadolinium in the Tissue of Patients with Nephrogenic Systemic Fibrosis”;  PI: Eric Simpson, MD</p>	2009
<p><i>Sub-I, Investigator-Initiated Study</i>  “Staphylococcal colonization and the subsequent risk of serious infection in rheumatic disease patients receiving biologic therapy; a role for decolonization?”;  PI: Kevin Winthrop, MD</p>	2007

**PEER-REVIEWED PUBLICATIONS**

Blauvelt, A., A. Chiricozzi, **B.D. Ehst**, and M.G. Lebwohl. (2023). Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review. *Advances in Therapy* 40(8):3410-3433.

Menter, A., T. Bhutani, **B. Ehst**, B. Elewski, and A. Jacobson. (2022). Narrative review of the emerging therapeutic role of brodalumab in difficult-to-treat psoriasis. *Dermatologic Therapy* 12(6):1289-1302.

Worm, M., J.P. Thyssen, S. Schliemann, A. Bauer, V. Shi, **B. Ehst**, S. Tillman, S. Korn, K. Resen and T. Agner. (2022). The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial. *The British Journal of Dermatology* 187(1):42-51.

- Lebwohl, M., L. Stein Gold, B. Strober, K. Papp, A. Armstrong, J. Bagel, L. Kircik, **B. Ehst**, H. Chih-ho Hong, J. Soung, J. Fromowitz, S. Guenther, S.C. Piscitelli, D.S. Rubenstein, P.M. Brown, A.M. Tallman and R. Bissonette. (2021). Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. *The New England Journal of Medicine* 385(24):2219-29.
- Ehst, B.**, Z. Wang, J. Leitenberger, D. McClanahan, R. De La Torre, E. Sawka, A.G. Ortega-Loayza, J. Strunck, T. Greiling, E. Simpson, and Y. Liu. (2021). Synergistic induction of IL-23 by TNF $\alpha$ , IL-17A, and EGF in keratinocytes. *Cytokine* 138(155357):1-6.
- Siegel, S.A.R., K. L. Winthrop, **B.D. Ehst** and A. Ortega Loayza. (2019). Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C. *The British Journal of Dermatology* 180(5):1232-33.
- Mott, S.E., Z.G. Pena, R.I. Spain, K.P. White and **B.D. Ehst**. (2016). Nicolau syndrome and localized panniculitis: a report of dual diagnoses with an emphasis on morphea profunda-like changes following injection with glatiramer acetate. *The Journal of Cutaneous Pathology* 43(11):1056-61.
- Patel, A.B., A.R. Solomon, M.J. Mauro and **B.D. Ehst**. (2016). Unique cutaneous reaction to second- and third-generation tyrosine kinase inhibitors for chronic myeloid leukemia. *Dermatology* 232(1):122-5.
- Curtis, J.R., M.I. Danila, L. Chen, B. Chan, **B. Ehst**, F. Xie, K.L. Winthrop and H. Yun. (2016). Risk of cardiovascular outcomes among psoriasis patients treated with biologics and other systemic agents. *Journal of Psoriasis and Psoriatic Arthritis* 1(3):128-37.
- Papp, K.A., M.A. Menter, M. Abe, B. Elewski, S.R. Feldman, A.B. Gottlieb, R. Langley, T. Luger, D. Thaci, M. Buonanno, P. Gupta, J. Proulx, S. Lan, R. Wolk; **OPT Pivotal 1 and OPT Pivotal 2 investigators**. (2015). Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. *The British Journal of Dermatology*. 143(4):949-61.
- Garg, N., B. Truong, J.H. Ku, T.S. Devere, **B.D. Ehst**, A. Blauvelt and A.A. Deodhar. (2015). A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinic. *Clinical Rheumatology* 34(10):1745-51.
- Truong, B., N. Rich-Garg, **B.D. Ehst**, A.A. Deodhar, J.H. Ku, K. Vakil-Gilani, A. Danve and A. Blauvelt. (2015). Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis. *Clinical, Cosmetic and Investigational Dermatology* 8:563-9.
- Varley, C.D., A.A. Deodhar, **B.D. Ehst**, A. Bakke, A. Blauvelt, R. Vega, S. Yamashita and K.L. Winthrop. (2014). Persistence of *Staphylococcus aureus* colonization among individuals with immune-mediated inflammatory diseases treated with TNF-inhibitor therapy. *Rheumatology* 53(2):332-7.
- Simpson, B., S. Foster, J.H. Ku, E.L. Simpson and **B.D. Ehst**. (2014). Triple antibiotic combination therapy may improve but not resolve granuloma annulare. *Dermatologic Therapy* 27(6):343-7.

- Ku, J.H., K.L. Winthrop, C.D. Varley, A. Sullivan, **B.D. Ehst**, A. Blauvelt and A.A. Deodhar. (2013). Implications for biologic therapy: *Staphylococcus aureus* decolonization of individuals with a history of recurrent skin and soft tissue infection. *JAMA Dermatology* 149(8):986-9.
- Jack, A., M.J. Mauro and **B.D. Ehst**. (2013). Pityriasis rubra pilaris-like eruption associated with the multi-kinase inhibitor ponatinib. *The Journal of the American Academy of Dermatology* 69(5):e249-50.
- Griffith-Bauer, K., M. O'Hearn and **B.D. Ehst**. (2012). Chronic ulcerative herpes simplex virus infection of the vulva. *Case Reports in Dermatology* 4:192-6.
- Goreshi, R., A. Samrao and **B.D. Ehst**. (2012). Double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene. *The Journal of Drugs in Dermatology* 11(12):1422-6.
- Perez-Rodriguez, J., S. Lai, **B.D. Ehst**, D.M. Fine and D.A. Bluemke. (2009). Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment—report of 33 cases. *Radiology* 250(2):371-7.
- Knol A.C., **B.D. Ehst**, A. Dompmartin, G. Quéreux, J.M. Nguyen, F. Comoz, J.J. Renaut, A. Khammari, E.C. Vonderheid and B. Dréno. (2009). Toll-like receptor 2, 4, 7 and 9 expression in primary cutaneous CD30+ T-cell lymphoma. *The British Journal of Dermatology* 161(6):1414-6.
- Ehst, B.D.**, B. Dréno and E.C. Vonderheid. (2008). Primary cutaneous CD30+ anaplastic large cell lymphoma responds to imiquimod cream. *The European Journal of Dermatology* 18(4):467-8.
- Fonder, M.A., D.L. Cummins, **B.D. Ehst**, G.J. Anhalt and J.H. Meyerle. (2006). Adalimumab therapy for recalcitrant pyoderma gangrenosum. *The Journal of Burns and Wounds* 5:66-71.
- Janssen, E.M., N.M. Droin, E.E. Lemmens, M.J. Pinkoski, S.J. Bensinger, **B.D. Ehst**, T.S. Griffith, D.R. Green, S.P. Schoenberger. (2005). CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. *Nature* 434(7029):88-93.
- Richards, D.M., S.L. Dalheimer, **B.D. Ehst**, T.L. Vanasek, M.K. Jenkins, M.I. Hertz and D.L. Mueller. (2004). Indirect minor histocompatibility antigen presentation by allograft recipient cells in the draining lymph node leads to the activation and clonal expansion of CD4<sup>+</sup> T cells that cause obliterative airways disease. *The Journal of Immunology* 172(6):3469-3479.
- Ehst, B.D.** and E.M. Warshaw. (2004). Alcohol-induced, application site-erythema after topical immunomodulator use and its inhibition by aspirin. *The Archives of Dermatology* 140(8):1014-1015.
- Ehst, B.D.**, E. Ingulli and M.K. Jenkins. (2003). Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection. *The American Journal of Transplantation* 3(11):1355-1362.
- Itano, A.A., S.J. McSorley, R.L. Reinhardt, **B.D. Ehst**, E. Ingulli, A.Y. Rudensky and M.K. Jenkins. (2003). Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. *Immunity* 19(1):47-57.

McSorley, S.J., **B.D. Ehst**, Y. Yu and A.T. Gewirtz. (2002). Bacterial flagellin is an effective adjuvant for CD4<sup>+</sup> T cells in vivo. *The Journal of Immunology* 169:3914-3919.

Sperling, A.I., J.A. Auger, **B.D. Ehst**, I.C. Rulifson, C.B. Thompson and J.A. Bluestone. (1996). CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. *The Journal of Immunology* 157:3909-3917.

## REVIEWS

Blauvelt, A., A. Chiricozzi and **B.D. Ehst**. (2020). Bimekizumab. *Current Dermatology Reports* 9:36-42.

**Ehst, B.D.**, K. Minzer-Conzetti, A. Swerdlin and T.S. Devere. (2010). Cutaneous manifestations of internal malignancy. *Current Problems in Surgery* 47(5):377-448.

## BOOK CHAPTERS

**Ehst, B.D.** and A. Blauvelt. (2012). Skin disease in acute and chronic immunosuppression. Chapter in *Fitzpatrick's Dermatology in General Medicine, 8<sup>th</sup> Edition*.

## OTHER PUBLICATIONS

Blauvelt, A. and **B.D. Ehst**. (2020). Do IL-17 inhibitors increase risk of respiratory tract infections? *Journal of the American Academy of Dermatology* S0190-9622(20)32100-9.

Winthrop, K.L., S.A.R. Siegel, L. Chen, H. Yun, B. Chan, J.W. Baddley, **B.D. Ehst** and J.R. Curtis. (2016). Comparative infectious risk of immunosuppressive therapies used in psoriasis. *Journal of Psoriasis and Psoriatic Arthritis* 2(1):44-50.

**Ehst, B.D.** (2013). Oral hairy leukoplakia. *CDS: Dermatology Online*;  
<http://www.decisionsupportinmedicine.com/>

Blauvelt, A. and **B.D. Ehst**. (2012). Pathophysiology of psoriasis. In B. Rose (Ed.), *UpToDate*. Available from <http://www.uptodate.com/home>

**Ehst, B.D.** and B.A. Cohen (2006). Case of the month: *Staphylococcus aureus* abscess due to "skin popping." *Johns Hopkins Advanced Studies in Medicine* 6(3&4):151&198. Available at <http://www.jhasim.com/index.cfm>

**Ehst, B.D.** (2002). Design and Characterization of a Model of Murine Skin Graft Rejection: Visualizing the Immune Response Against a Defined Minor Transplantation Antigen. *Dissertation Abstracts International*, 62(11), 5019. (UMI No. 3034442)

## CONFERENCE ABSTRACTS/POSTERS/PRESENTATIONS

A. Blauvelt, J.E. Gudjonsson, R. Matheson, R. Liu, L. Shi, H. Photowala and **B. Ehst**. (2023, May). *High-induction dosing of risankizumab in patients with moderate-to-severe plaque psoriasis: interim results from*



*the phase 2 Knockout study*. Poster presented at the 1st International Societies for Investigative Dermatology Meeting, Tokyo, Japan.

V.H. Prajapati, B. Glick, L. Spelman, I. Figueras Nart, B. Calimlim, B. Ladzinski, T. Wu, Y. Liu, J. Davis, H. Aydin and **B. Ehst**. (2022, October). *Incremental improvements after switching from dupilumab (DUPI) to upadacitinib (UPA) in the Heads-Up open-label extension (OLE) study*. Poster presented at Fall Clinical Dermatology Conference, Las Vegas, NV.

V.H. Prajapati, B. Glick, L. Spelman, I. Figueras Nart, B. Calimlim, B. Ladzinski, T. Wu, Y. Liu, J. Davis, H. Aydin and **B. Ehst**. (2022, May). *Incremental improvements after switching from dupilumab (DUPI) to upadacitinib (UPA) in the Heads-Up open-label extension (OLE) study*. Poster presented at the Annual Meeting of the Society of Investigative Dermatology, Portland, OR.

L. Stein Gold, **B. Ehst**, L.K. Ferris, P.M. Brown, D.S. Rubenstein, A.M. Tallman and J. Bagel. (2022, April). *Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Additional Efficacy Outcomes from a Long-Term Extension Trial*. Poster presented at the Innovations in Dermatology Spring 2022 meeting, Scottsdale, AZ.

D. Maslin, Y. Mihaylov, D. Macaro, N. Carpenter, G. Mehraei, M. Bodmer, J. Zung, M. Plinio, D. McHale and **B. Ehst**. (2022, March). *A phase 2 study investigating the effect of EDP1815, an orally-delivered, anti-inflammatory, gut-restricted commensal microbe in the treatment of mild and moderate plaque psoriasis*. Late breaking abstract presented at the Annual Meeting of the American Academy of Dermatology, Boston, MA.

L. Stein Gold, **B. Ehst**, L.K. Ferris, P.M. Brown, D.S. Rubenstein and J. Bagel. (2022, March). *Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from a Long-Term Extension Trial*. Poster presented at the Annual Meeting of the American Academy of Dermatology, Boston, MA.

M. Lebwohl, L. Stein Gold, B. Strober, K. Papp, A. Armstrong, J. Bagel, L. Kircik, **B. Ehst**, H. Chih-ho Hong, J. Soung, J. Fromowitz, S. Guenther, S.C. Piscitelli, D.S. Rubenstein, P.M. Brown, A.M. Tallman and R. Bissonnette. (2021, August). *Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials*. Poster and abstract presented at the DERM2021 NP/PA CME Conference.

M. Lebwohl, L. Stein Gold, B. Strober, K. Papp, A. Armstrong, J. Bagel, L. Kircik, **B. Ehst**, H. Chih-ho Hong, J. Soung, J. Fromowitz, S. Guenther, S.C. Piscitelli, D.S. Rubenstein, P.M. Brown, A.M. Tallman and R. Bissonnette. (2021, June). *Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials*. Poster and abstract presented at the Society of Dermatology Physician Assistants 2021 Summer Conference.

M. Lebwohl, L. Stein Gold, B. Strober, K. Papp, A. Armstrong, J. Bagel, L. Kircik, **B. Ehst**, H. Chih-ho Hong, J. Soung, J. Fromowitz, S. Guenther, S.C. Piscitelli, D.S. Rubenstein, P.M. Brown, A.M. Tallman and R. Bissonnette. (2021, June). *Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials*. Poster and abstract presented at the Maui Derm NP+PA 2021 Summer Conference, Las Vegas, NV.

M. Lebwohl, L. Stein Gold, B. Strober, K. Papp, A. Armstrong, J. Bagel, L. Kircik, **B. Ehst**, H. Chih-ho Hong, J. Soung, J. Fromowitz, S. Guenther, S.C. Piscitelli, D.S. Rubenstein, P.M. Brown, A.M. Tallman and R. Bissonnette. (2021, January). *Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis:*

*Efficacy and Safety in Two Pivotal Phase 3 Trials*. Abstract presented at the Winter Clinical Dermatology Virtual Conference.

Worm, M., J. Thyssen, S. Schliemann, A. Bauer, V. Shi, **B. Ehst**, S. Tillmann, S. Korn, K. Resen Andersen and T. Agner. (2020, October). *The topical pan-JAK inhibitor delgocitinib cream demonstrates dose response in a 16-week phase 2b trial in chronic hand eczema*. Late breaking abstract presented at the 29<sup>th</sup> European Academy of Dermatology and Venereology Virtual Congress.

M. Lebwohl, L. Stein Gold, B. Strober, K. Papp, A. Armstrong, J. Bagel, L. Kircik, **B. Ehst**, H. Chih-ho Hong, J. Soung, J. Fromowitz, S. Guenther, S.C. Piscitelli, D.S. Rubenstein, P.M. Brown, A.M. Tallman and R. Bissonnette. (2020, October). *Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials*. Late breaking abstract presented at the 29<sup>th</sup> European Academy of Dermatology and Venereology Virtual Congress.

Brunner, M., A. Armstrong, B. Strober, **B. Ehst**, A. Jacobson and U. Ntuen. (2020, October). *Absolute PASI response up to 52 weeks with brodalumab in patients with moderate-to-severe plaque psoriasis*. Poster presentation given at the 18<sup>th</sup> Annual Society of Dermatology Physician Assistants Virtual Meeting.

Krueger, J.G., D.M. Pariser, E. Muscianisi, F. Kianifard, J. Steadman, R.P. Sarkar, **B.D. Ehst** and A.F. Alexis. (2020, June). *Response to Treatment With Secukinumab in Obese Patients With Moderate to Severe Psoriasis*. Poster presentation given at the American Academy of Dermatology Virtual Meeting.

**Ehst, B.**, G. Han, S. Guenther, K. Eads and A. Jacobson. (2019, October). *Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration <10 and ≥10 Years: Analysis of Two Phase 3 Studies*. Poster presentation given at the 39<sup>th</sup> Annual Fall Clinical Dermatology Conference for Dermatologists, Las Vegas, NV.

Krueger, J.G., A.W. Armstrong, **B.D. Ehst**, J. Steadman, F. Kianifard and E. Muscianisi. (2019, October). *Effect of Secukinumab Treatment on Measures of Insulin Resistance in Patients With Psoriasis*. Poster presentation given at the 28<sup>th</sup> European Academy of Dermatology and Venereology Congress, Madrid, Spain.

Kircik, L., A. Armstrong, **B. Ehst**, R.S. Ho and A. Jacobson. (2019, February). *Effects of brodalumab on anxiety and depression in patients with psoriasis and moderate-to-severe anxiety and depression: results from a phase 3, randomized, controlled clinical trial*. Poster presentation given at the 43<sup>rd</sup> Annual Hawaii Dermatology Seminar, The Big Island, HI.

Siegel, S.A.R., K.L. Winthrop, **B.D. Ehst** and A.G. Ortega-Loayza. (2017, April). *Secukinumab treatment of individuals with psoriasis infected with hepatitis B and/or hepatitis C virus*. Poster presentation given at the 76th Annual Meeting of the Society of Investigative Dermatology, Portland, OR.

Winthrop, K.L., S.A.R. Siegel, L. Chen, B. Chan, J.W. Baddley, A.J. Taylor, H. Yen, **B.D. Ehst** and J.R. Curtis. (2015, June). *Risk of herpes zoster and non-viral opportunistic infection in a psoriatic cohort*. Poster presentation given at the 23<sup>rd</sup> World Congress of Dermatology, Vancouver, British Columbia.

Li, C., A.A. Deodhar and **B.D. Ehst**. (2015, June). *“Real-world” use of ustekinumab for psoriasis, including palmar-plantar disease, and psoriatic arthritis: a comprehensive, retrospective chart review of an academic*

outpatient clinic. Poster presentation given at the 23<sup>rd</sup> World Congress of Dermatology, Vancouver, British Columbia.

Siegel, S., K.L. Winthrop, W. Naugler and **B.D. Ehst**. (2015, May). *Ustekinumab treatment of psoriatics infected with hepatitis B and/or hepatitis C*. Poster presentation given at the 75th Annual Meeting of the Society of Investigative Dermatology, Atlanta, GA.

Patel, A., A. Solomon, M. Mauro and **B.D. Ehst**. (2015, May). *Unique cutaneous reaction to second- and third-generation tyrosine kinase inhibitors for chronic myeloid leukemia*. Poster presentation given at the 75th Annual Meeting of the Society of Investigative Dermatology, Atlanta, GA.

Golden, S., M. Heinrich and **B.D. Ehst**. (2015, January). *Ponatinib-Induced Pityriasis Rubra Pilaris-Like Eruption: A Report of Six Cases*. Poster presentation given at the 2015 Maui Dermatology Conference, Maui, HI.

Simpson, B., S. Foster, J.H. Ku, E.L. Simpson and **B.D. Ehst**. (2013, May). *Triple antibiotic combination therapy may improve but not resolve granuloma annulare*. Poster presentation given at the 2013 International Investigative Dermatology Meeting, Edinburgh, Scotland.

Liu, Y., D. McClanahan, S. Persaud, Y. Wang and **B. Ehst**. (2013, May). *The loss of Piasy activates IL-23 expression from keratinocytes in response to IL-17 and TNF, a positive feedback mechanism for Th17 activation in psoriasis*. Poster presentation given at the 2013 International Investigative Dermatology Meeting, Edinburgh, Scotland.

Garg, A., B. Truong, J. Ku, A. Blauvelt, **B. Ehst** and A. Deodhar. (2012, November). *Simple questions in the dermatology office may reasonably exclude, but do not reliably identify psoriatic arthritis patients: results from the Center of Excellence for Psoriasis and Psoriatic Arthritis*. Poster presentation given at the 76<sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology, Washington, DC.

Garg, A., B. Truong, J. Ku, A. Blauvelt, **B. Ehst** and A. Deodhar. (2012, June). *Simple questions in the dermatology office may reasonably exclude, but do not reliably identify psoriatic arthritis patients: results from the Center of Excellence for Psoriasis and Psoriatic Arthritis*. Oral and poster presentation given at the 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Stockholm, Sweden.

Goreschi, R., A. Samrao and **B.D. Ehst**. (2012, May). *Double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene*. Oral and poster presentation given at the 72<sup>nd</sup> Annual Meeting of the Society of Investigative Dermatology, Raleigh, NC.

Varley, C.D., K. Griffith-Bauer, A.A. Deodhar, **B.D. Ehst**, A. Bakke, A. Blauvelt, R. Vega and K.L. Winthrop. (2011, July). *Higher prevalence of Staphylococcus aureus colonization in psoriatic patients may predispose to incident infections*. Oral and poster presentation given at the 2011 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), Naples, Italy.

Samrao, A., B. Truong, A. Deodhar, J. Gelfand, T. Devere, **B. Ehst** and A. Blauvelt. (2011, May). *High prevalence of psoriatic arthritis with a significant impact on quality of life in psoriasis patients evaluated at*

a multidisciplinary center. Poster presentation given at the 71<sup>st</sup> Annual Meeting of the Society of Investigative Dermatology, Phoenix, AZ.

Griffith-Bauer, K., C.D. Varley, K.L. Winthrop, A. Blauvelt, A.A. Deodhar, A. Bakke, R. Vega and **B.D. Ehst**. (2011, May). *Staphylococcus aureus* colonization does not increase the rate of infection among psoriasis patients using biologic therapy. Poster presentation given at the 71<sup>st</sup> Annual Meeting of the Society of Investigative Dermatology, Phoenix, AZ.

Varley, C., A.A. Deodhar, **B. Ehst**, A. Bakke, A. Blauvelt, R. Vega and K. Winthrop. (2010, November). *Colonization and Infection by Staphylococcus Aureus Among Those Using Biologic Therapy*. Oral and poster presentation given at the 74<sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology, Atlanta, GA

Deodhar, A.A., S. Yamashita, **B. Ehst**, A. Bakke, A. Blauvelt, B. Andrews, R. Vega and K. Winthrop. (2009, October). *Prevalence of Staphylococcus Aureus Colonization Among Those Using Biologic Therapy*. Poster presentation given at the 73<sup>rd</sup> Annual Scientific Meeting of the American College of Rheumatology, Philadelphia, PA

**Ehst, B.D.** and F. Tausk. (2006, March). *Annular elastolytic granuloma: A case and discussion*. Oral presentation given at the Gross & Microscopic Dermatology Symposium at the 64<sup>th</sup> Annual American Academy of Dermatology Meeting, San Francisco, CA.

**Ehst, B.D.** (2001, October). *Contributions of CD4 and CD8 T cells in the rejection of skin allografts*. Oral presentation given at the University of Minnesota Medical School Annual M.D./Ph.D. Conference, Minneapolis, MN.

**Ehst, B.D.** and M.K. Jenkins. (2001, May). *Acute rejection of a skin graft expressing a defined minor antigen*. Oral presentation given at Transplant 2001, the Joint American Transplant Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL.

**Ehst, B.D.** and M.K. Jenkins. (2001, January). *Acute rejection of a skin graft expressing a defined minor antigen*. Poster presentation given at the Keystone Symposia on Regulation of Immunity and Autoimmunity, Keystone, CO.

**Ehst, B.D.** and M.K. Jenkins. (2000, November). *Visualization of the immune response against a skin graft expressing a single model minor antigen*. Oral and poster presentation given at the 29<sup>th</sup> Annual Autumn Immunology Conference, Chicago, IL.

**Ehst, B.D.**, K.A. Pape and M.K. Jenkins. (2000, May). *Antigen-specific CD4<sup>+</sup> cells prolong the clonal expansion of CD8<sup>+</sup> cells*. Poster presentation given at Immunology 2000, the American Association of Immunologists and Clinical Immunology Society Joint Annual Meeting, Seattle, WA.

**Ehst, B.D.** and M.K. Jenkins. (1999, November). *Development of a murine model of skin graft rejection across a single minor-antigenic disparity*. Oral and poster presentation given at the 28<sup>th</sup> Annual Autumn Immunology Conference, Chicago, IL.

**Ehst, B.D.**, A.I. Sperling and J.A. Bluestone. (1996, May). *Requirements for activation and proliferation of*

*TCR $\gamma\delta$  intestinal intraepithelial lymphocytes.* Poster presentation given at the University of Chicago Senior Biological Sciences Honors Forum, Chicago, IL.

**Ehst, B.D.**, A.I. Sperling, J.A. Auger, I.C. Rulifson and J.A. Bluestone. (1995, November). *Costimulation but not TCR ligation regulates late T Cell expansion and survival.* Oral and poster presentation given at the 24<sup>th</sup> Annual Autumn Immunology Conference, Chicago, IL.

## INVITED LECTURES

### International/National

**Ehst, B.D.** (2023, November). *Optimizing the Use of Biologics.* Lecture given at the North American IPC Psoriasis Master Class, Las Vegas, NV.

**Ehst, B.D.** (2023, November). *Management of Psoriasis involving High Impact Areas.* Lecture given at the North American IPC Psoriasis Master Class, Las Vegas, NV.

**Ehst, B.D.** (2018, September). *Atopic dermatitis: Past, present and future.* Lecture given at the 2018 Annual Meeting of the American Society of Allergy Nurses, Seaside, OR.

**Ehst, B.D.** (2018, February). *Update on HIV and the Skin.* Lecture given at the Dermatology Nurses' Association's 36<sup>th</sup> Annual Convention, San Diego, CA.

**Ehst, B.D.** (2017, March). *Update on HIV and the Skin.* Lecture given at the Dermatology Nurses' Association's 35<sup>th</sup> Annual Convention, Orlando, FL.

**Ehst, B.D.** (2015, March). *Tumor necrosis factor inhibitors: Pre-treatment workup, dosing and monitoring.* Lecture given at the 73<sup>rd</sup> Annual American Academy of Dermatology Meeting, San Francisco, CA.

**Ehst, B.D.** (2012, March). *Update on HIV Skin Disease.* Lecture given at the Dermatology Review Course at the 70<sup>th</sup> Annual American Academy of Dermatology Meeting, San Diego, CA.

**Ehst, B.D.** (2011, March). *Infectious diseases and STDs in Dermatology.* Lecture given at the Dermatology Nurses' Association's 29<sup>th</sup> Annual Convention, San Diego, CA.

**Ehst, B.D.** (2011, February). *Update on HIV Skin Disease.* Lecture given at the Dermatology Review Course at the 69<sup>th</sup> Annual American Academy of Dermatology Meeting, New Orleans, LA.

### Regional/Local

**Ehst, B.D.** (2023, October). *Challenging unknowns.* Lecture given at the 10<sup>th</sup> Annual Oregon Society of Dermatology Associates meeting, Portland, OR.

**Ehst, B.D.** (2020, October). *Pso is it psoriasis, or not...?* Lecture given at the Annual Oregon Society of Dermatology Associates virtual meeting, Portland, OR.

**Ehst, B.D.** (2016, October). *What's new in psoriasis?* Lecture given at the Dermatology Update

Conference, Continuing Education for Primary Care series, HealthPartners Institute, St. Louis Park, MN.

**Ehst, B.D.** (2015, January). *Update on HIV and the Skin; Psoriasis Potpourri*. Lectures given at the biennial meeting of the Idaho Dermatology Society, Boise, ID.

**Ehst, B.D.** (2014, February). *HIV and Dermatology Update*. Lecture given at the monthly meeting of the Oregon Dermatology Society, Portland, OR.

**Ehst, B.D.** (2013, October). *Psoriasis Update: Current and future therapies*. Lecture given at the 1<sup>st</sup> Annual Oregon Society of Dermatology Associates meeting, Portland, OR.

**Ehst, B.D.** (2013, September). *Psoriasis Update: Co-morbidities*. Lecture given at the 9<sup>th</sup> Annual Dermatology for Primary Care Update meeting, Portland, OR.

**Ehst, B.D.** (2013, May). *Dermatologic unknowns*. Talk given to the Oregon Dermatologic Physician Assistant's Society, Portland, OR.

**Ehst, B.D.** (2013, February). *Treatment of common skin conditions*. Lecture given at the 23<sup>rd</sup> Annual Lane County Nurse Practitioner Conference, Eugene, OR.

**Ehst, B.D.** (2012, November). *Skin manifestations and mimics of infectious disease, parts 1 and 2*. Lectures given at the 22<sup>nd</sup> Annual Meeting of the Infectious Diseases Society of Oregon, Eugene, OR.

**Ehst, B.D.** (2012, March). *Dermatologic unknowns*. Lecture given at the 22<sup>nd</sup> Annual Lane County Nurse Practitioner Conference, Eugene, OR.

**Ehst, B.D.** (2011, September). *Dermatologic unknowns*. Lecture given at the 7<sup>th</sup> Annual Dermatology for Primary Care Update meeting, Portland, OR.

**Ehst, B.D.** (2011, April). *Old and New Issues in HIV Skin Disease*. Lecture given at the April breakfast meeting of the Northwest AIDS Education and Training Center, Portland, OR.

**Ehst, B.D.** (2010, February). *Common skin conditions*. Lecture given at the Breakout Session of the 41<sup>st</sup> Annual Primary Care Review conference, Portland, OR.

**Ehst, B.D.** (2009, September). *Body-modification: tattoos and piercings*. Lecture given at the 5<sup>th</sup> Annual Dermatology for Primary Care Update meeting, Portland, OR.

**Ehst, B.D.** (2009, August). *MRSA update*. Lecture given at the 61<sup>st</sup> Annual Pacific Dermatologic Association meeting, Portland, OR.

**Ehst, B.D.** (2009, February). *Body-modification: tattoos and piercings*. Lecture given at the Pediatrics Plenary Session of the 40<sup>th</sup> Annual Family Medicine & Primary Care Review conference, Portland, OR.

**Ehst, B.D.** (2009, January). *Current issues in HIV skin disease*. Talk given to the Oregon Dermatologic Physician Assistant's Society, Beaverton, OR.

**Ehst, B.D.** (2006, November). *Nephrogenic systemic fibrosis*. Lecture given at Grand Rounds, Department of Nephrology, Johns Hopkins Bayview Medical Center, Baltimore, MD.

**Ehst, B.D.** (2002, September). *Visualizing T cells in skin allografts*. “Dermatologic Research in Progress” lecture given at Grand Rounds, Department of Dermatology, Indiana University, Indianapolis, IN.

## **SPEAKING ENGAGEMENTS**

**SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib)**. National speaker board product theaters, in-person and virtual talks on behalf of AbbVie, Inc.; (5) events in 2021, (3) events in 2022, (3) events in 2023 at locations including Dayton, OR, Portland, OR, and Lake Oswego, OR

**COSENTYX® (secukinumab)**. National speaker board product theaters, video recordings, in-person and virtual talks, and non-branded educational talks, webinars, and video recordings on behalf of Novartis Pharmaceuticals, Inc.; (8) events in 2017, (16) events in 2018, (19) events in 2019, (12) events in 2020, (1) event in 2021 at locations including Anchorage, AK, Palo Alto, CA, Fresno, CA, Kauai, HI, Lake Oswego, OR, Portland, OR, Roseburg, OR, Medford, OR, Eugene, OR, Bend, OR, Salem, OR, Tualatin, OR, Vancouver, WA, and Longview, WA

**DUPIXENT® (dupilumab)**. National speaker board product theaters, in-person and virtual talks on behalf of Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis US, LLC; (2) events in 2017, (14) events in 2018, (13) events in 2019, (24) events in 2020, (11) events in 2021, (7) events in 2022, (4) events in 2023 at locations including Girdwood, AK, San Diego, CA, San Francisco, CA, Fort Collins, CO, Lahaina, HI, Astoria, OR, Roseburg, OR, Hillsboro, OR, Portland, OR, Lake Oswego, OR, LaGrande, OR, Salem, OR, Bend, OR, Sunriver, OR, Seaside, OR, Keizer, OR, Clackamas, OR, McMinnville, OR, Tigard, OR, Spokane, WA, Tri-Cities, WA, and Vancouver, WA

**TALTZ® (ixekizumab) and OLUMIANT® (baricitinib)**. National speaker board in-person and virtual talks, and non-branded educational talks on behalf of Lilly USA, LLC; (16) events in 2018, (12) events in 2019, (12) events in 2020, (10) events in 2021, (9) events in 2022, (9) events in 2023 at locations including Anchorage, AK, Wasilla, AK, Phoenix, AZ, Washington, DC, Honolulu, HI, Kailua, HI, Kihei, HI, Wailuku, HI, Paia, HI, Kahului, HI, Bend, OR, Hillsboro, OR, Portland, OR, Astoria, OR, Salem, OR, Klamath Falls, OR, Jacksonville, OR, Corvallis, OR, Tigard, OR, Lake Oswego, OR, McMinnville, OR, Bozeman, MT, Yakima, WA, Kennewick, WA, Spokane, WA, Kalama, WA, Pasco, WA, Seattle, WA, and Olympia, WA

**SILIQ® (brodalumab)**. National speaker board in-person and virtual talks on behalf of Bausch Health US, LLC - Ortho Dermatologics; (2) events in 2019, (1) event in 2020 at locations including Portland, OR, Medford, OR, and Lacey, WA

**OPZELURA® (ruxolitinib cream)**. National speaker board in-person and virtual talks on behalf of Incyte Corporation; (1) event in 2021, (3) events in 2022, (2) events in 2023 at locations including Eugene, OR, Tualatin, OR, and Lake Oswego, OR

**ADBRY® (tralokinumab)**. National speaker board in-person and virtual talks on behalf of LEO Pharma, Inc.; (6) events in 2022, (2) events in 2023 at locations including San Jose, CA, Salem, OR, Vancouver, WA, and Seattle, WA

VTAMA® (*tapinarof cream*). National speaker board in-person and virtual talks on behalf of Dermavant Sciences, Inc.; (4) events in 2022, (1) event in 2023 at locations including Lake Oswego, OR, Salem, OR, Portland, OR and Gresham, OR

#### OTHER PROFESSIONAL PRESENTATIONS

*Unmet needs in atopic dermatitis, and BTLA checkpoint agonism*. Presentation given (September 2023) at the AnaptysBio investigator meeting for ANBo32-201 clinical trial, Miami, FL.

*From an idea to market: Clinical trials 101*. Lecture given (October, 2022) for the Tualatin, OR branch of the American Association of University Women, Tualatin, OR.

*Psoriasis 101*. Educational webinar (August, 2022) for the National Psoriasis Foundation's Virtual Grand Rounds, Portland, OR.

*Q&A about psoriasis*. Educational webinar (August, 2020) for the National Psoriasis Foundation, Portland, OR.

*Psoriasis and family planning*. Educational webinar (July, 2020) for the National Psoriasis Foundation's "Updates in Psoriasis Enduring Content" Series, Portland, OR.

*Psoriasis 101*. Lecture given at Portland Dermatology clinic (2019, August) on behalf of the National Psoriasis Foundation, Portland, OR.

*Psoriasis comorbidities*. Lecture given for the Early Careers symposium of "Psoriasis Day" event (September, 2018) on behalf of the National Psoriasis Foundation and Oregon Health & Science University, Portland, OR.

*Updates in Psoriasis*. Lecture given for the Central Oregon Advanced Practice Providers Network (2018, February) on behalf of the National Psoriasis Foundation, Bend, OR.

*Psoriasis 101*. Lecture given at internal medicine grand rounds (2017, November) on behalf of the National Psoriasis Foundation, Legacy Emmanuel Hospital, Portland, OR.

*Targets, Treatments, and What it Means for You*. Lecture given at the 'More Than Skin Deep' event (2017, April) of the National Psoriasis Foundation, Portland, OR.

*Pathogenesis and Genetics of Psoriasis and PsA; Management of Psoriasis and PsA- Biologics*. Lectures given at the NPF-GRAPPA collaborative series 'Advancing Knowledge and Practice in Psoriasis and Psoriatic Arthritis' meeting (2015, May), Portland, OR.

*Psoriatic Arthritis*. Lecture given at the 'Be Joint Smart' conference (2012, October) of the National Psoriasis Foundation and the Arthritis Foundation, Portland, OR

Desai, N. and **B.D. Ehst**. (2011, February). A "Bee"wildering rash. Presented at the Gross & Microscopic Dermatology Symposium at the 69th Annual American Academy of Dermatology Meeting, New Orleans, LA.



N. Desai and **B.D. Ehst**. (2009, August). *Borderline lepromatous leprosy*.  
 K. White, **B.D. Ehst** and C. White. (2009, August). *Eruptive disseminated spitz nevi*.  
 K. Minzer-Conzetti and **B.D. Ehst**. (2009, August). *Huriez syndrome*.  
 Case presentations at the 61<sup>st</sup> Annual Pacific Dermatologic Association meeting, Portland, OR.

**Ehst, B.D.** (2004 - 2007, Spring & Fall). *Case presentations*. Semiannual Maryland Dermatologic Society Meeting, The Johns Hopkins Hospital, Baltimore, MD.

## SERVICE

---

### PROFESSIONAL AFFILIATIONS

International Psoriasis Council	2022 - PRESENT
American Association of Immunologists	2017 - PRESENT
	1996 - 2004
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis	2012 - PRESENT
National Psoriasis Foundation	2010 - PRESENT
Oregon Dermatology Society	2007 - PRESENT
Oregon Medical Association	2007 - PRESENT
American Academy of Dermatology	2004 - PRESENT
American Medical Association	2004 - PRESENT
Combined Psoriasis and Psoriatic Arthritis Clinics and Centers of North America	2012 - 2015
Society for Investigative Dermatology	2010 - 2015
Dermatology Foundation	2007 - 2015

### EDITORIAL ACTIVITIES

<i>Ad hoc reviewer</i> , Trends in Pharmacological Sciences	2023 - PRESENT
<i>Ad hoc reviewer</i> , Journal of Investigative Dermatology	2022 - PRESENT
<i>Ad hoc reviewer</i> , British Journal of Dermatology	2020 - PRESENT
<i>Ad hoc reviewer</i> , Journal of Psoriasis and Psoriatic Arthritis	2020 - PRESENT
<i>Ad hoc reviewer</i> , BioDrugs	2018 - 2019
<i>Ad hoc reviewer</i> , Association of American Medical Colleges, Monographs	2007 - 2019
<i>Ad hoc reviewer</i> , Clinical and Experimental Dermatology	2014 - 2016
<i>Faculty Member</i> , Section of Psoriasis & Other Inflammatory Diseases, Faculty of 1000, <a href="http://www.f1000.com/">http://www.f1000.com/</a>	2013 - 2016
<i>Ad hoc reviewer</i> , Dermatology Research and Practice	2014 - 2015
<i>Ad hoc reviewer</i> , National Institute of Standards and Technology, U.S. Department of Commerce	2013
<i>Ad hoc reviewer</i> , International Journal of STD & AIDS	2013

### COMMITTEES

<i>Member</i> , Clinician Improvement and Satisfaction Committee Dermatology group, HealthPartners, St. Paul, MN	2015 - 2017
---	-------------

<i>Member</i> , Departmental Budget Committee Department of Dermatology, Oregon Health & Science University, Portland, OR	2014 - 2015
<i>Chair</i> , Departmental Operations Improvement Committee Department of Dermatology, Oregon Health & Science University, Portland, OR	2014 - 2015
<i>Member</i> , Clinical Competency Committee Department of Dermatology, Oregon Health & Science University, Portland, OR	2013 - 2015
<i>Member</i> , Faculty Executive Committee Department of Dermatology, Oregon Health & Science University, Portland, OR	2010 - 2013
<i>Member</i> , Clinical Faculty Guideline Committee Department of Dermatology, Oregon Health & Science University, Portland, OR	2008 - 2013
<i>Representative</i> , House Staff Council The Johns Hopkins Hospital, Baltimore, MD	2004 - 2007
<i>Resident Representative</i> , Transitional Residency Coordinating Committee Hennepin County Medical Center, Minneapolis, MN	2003 - 2004
<i>Resident Representative</i> , Graduate Medical Education Committee Hennepin County Medical Center, Minneapolis, MN	2003 - 2004
<i>Representative</i> , Resident Council Hennepin County Medical Center, Minneapolis, MN	2003 - 2004
<b>VOLUNTEER ACTIVITIES</b>	
<i>Member</i> , Speaker Committee Oregon Dermatology Society, Portland, OR	2022 - Present
<i>Local Moderator</i> , NPF-GRAPPA collaborative series 'Advancing Knowledge and Practice in Psoriasis and Psoriatic Arthritis' meeting, Portland, OR	MAY 2015
<i>Faculty Leader</i> , Dermatology Student Interest Group Oregon Health & Science University, Portland, OR	2013 - 2015
<i>Member</i> , Executive Committee Oregon Dermatology Society, Portland, OR	2012 - 2015
<i>Volunteer</i> , Botswana-UPenn Partnership Princess Marina Hospital, Gaborone, Botswana	JAN 2014
<i>Co-director</i> , Dermatology Review Course at the 70 <sup>th</sup> Annual American Academy of Dermatology Meeting, San Diego, CA	MAR 2012

<i>Secretary/Treasurer,</i> Oregon Dermatology Society, Portland, OR	2011 - 2012
<i>Fundraiser, Vice-chair for the State of Oregon</i> Dermatology Foundation, Evanston, IL	2009 - 2011
<i>Coordinator for Departmental Grand Rounds,</i> Department of Dermatology Johns Hopkins University School of Medicine, Baltimore, MD	2006 - 2007
<i>Coordinator for Visiting Physicians,</i> Department of Dermatology Johns Hopkins University School of Medicine, Baltimore, MD	2005 - 2006
<i>Volunteer, Smiley's Family Practice Clinic</i> Fairview-University Medical Center, Minneapolis, MN	1998 - 2003

**SPECIALIZED CLINICAL ACTIVITIES**

<i>OHSU Dermatologic Clinic for HIV/AIDS</i> Established first subspecialty clinic at OHSU focusing on cutaneous issues in individuals with HIV/AIDS	2009 - 2015
<i>OHSU Center for Excellence in Psoriasis and Psoriatic Arthritis</i> <i>Member</i> (2008 - 2015) and <i>Co-Director</i> (2011 - 2015) of clinical team focusing on comprehensive multidisciplinary care for patients living with psoriasis and psoriatic arthritis	2008 - 2015

**CONTINUING EDUCATION**

<i>Participant, Pathways to Leadership Course</i> Oregon Health & Science University, Portland, OR	2011
---	------

**TEACHING**

---

*Educator's Portfolio available upon request*

**HONORS AND AWARDS**

---

<i>Recipient, Department of Dermatology Faculty Teaching Award,</i> Oregon Health & Science University	2015
<i>Portland Monthly</i> magazine's "Top Doctors"	2012, 2015
<i>Participant, National Institutes of Health Medical Scientist Training Program</i>	1996 - 2003
<i>Recipient, J. Thomas Livermore Award in Hematology,</i> Minnesota Medical Foundation	APR 2002

<i>Recipient, Young Investigator Award, Joint American Transplant Meeting of the American Society of Transplant Surgeons and American Society of Transplantation</i>	MAY 2001
<i>Recipient, National Institutes of Health Pre-Doctoral Training Grant in Immunology</i>	1999 – 2001
<i>Medical School Honors, University of Minnesota Medical School</i>	1996 - 1997
<i>Dean's List, University of Chicago</i>	1992 - 1996
<i>Recipient, Howard Hughes Summer Research Fellowship</i>	JUN 1995